Ce bulletin signale des articles du web anglophone portant sur les divers champs d'intervention de l'Institut national du cancer. La publication se fait sur un rythme quotidien.
In their paper published in the journal Nature, the group describes conducting transcriptomic, epigenomic and genomic analyses of prostate cancer tissue in patients in China and compared what they found with data from cancer patients in the west—and what they discovered as a result.
Studies have pointed to a link between colon cancer and a gut bacterium that produces DNA-damaging molecules. The discovery of a mutational signature linked to these bacteria in human colon cancer supports this association.
Despite accumulating papers and anecdotal reports of such tumor "hyper-progression," some cancer researchers wonder whether it is simply an illusion—whether the patients' tumors were destined to grow rapidly even before checkpoint inhibitor treatment.
The approval was based on the results of the late-stage, 805 patient-CASPIAN trial, which tested Imfinzi plus standard-of-care chemotherapy, or Imfinzi and chemotherapy with the addition of AstraZeneca’s in-house CTLA-4 drug tremelimumab, versus chemotherapy alone.
Only PD-1/PD-L1 immunotherapy to demonstrate a significant survival benefit in combination with etoposide and a choice of carboplatin or cisplatin chemotherapy.
A new framework from an international team of experts aims to help protect patients and providers, and conserve protective equipment for frontline health care workers.
Dozens of clinical studies are affected by the health system disruption caused by the coronavirus pandemic. Cell therapy trials could be particularly vulnerable, however, as they require extensive patient screening and, for some, the collection of patients' own immune cells.
This decision is being taken due to the urgent shift among clinical sites toward efforts to combat the COVID-19 pandemic, which has impacted the feasibility of completing the study within the shelf-life of the current ficlatuzumab clinical trial supply.